The arrival of immune checkpoint inhibitors has been reshaping the captivating landscape of cancer immunotherapy.
Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- LAG-3 Targeted Approach in Cancer Therapy
- Therapeutic Approaches for Novel LAG-3 Targeted Therapy
- Global LAG 3 Inhibitor Market Future Outlook
Download Report:
The arrival of immune checkpoint inhibitors has been reshaping the captivating landscape of cancer immunotherapy. Although these drugs have shown encouraging response in the management of several cancers but their market is mainly restrained by the tumor intrinsic resistance mechanisms remains a major challenge. The high medical needs for the identification of more alternative therapeutic targets has led to extensive research and development activities in this domain. Strikingly, lymphocyte activation gene-3 (LAG-3) is the emerging immune checkpoint and is considered as highly promising therapeutic target.
Eftilagimod Alpha (IMP321) is a soluble dimeric recombinant form of LAG-3, and is a first-in-class antigen presenting cell activator under clinical development. The drug was developed by Immutep and has completed three clinical trials in renal cell carcinoma, metastatic breast carcinoma, and melanoma with moderate success. The company is still processing the drug in new clinical trials to further exploring the therapeutic benefits of the drugs. Apart from this, Bristol Myers Squibb has developed Relatlimab which is LAG-3 blocking antibody that is being investigated with other agents in a variety of tumor types. Recently in 2021, FDA has accepted priority review for fixed dose combination of relatlimab and nivolumab in patients with unresectable or metastatic melanoma. The encouraging clinical response of these drugs have further surged the research and development activities in this sector.
Several pharmaceutical companies including Novartis, Bristol Meyer Squibb, F-star Therapeutics, Macrogenics, Boehringer Ingelheim, I-Mab Biopharma, and others have emerged out to be key players in the market which have developed robust pipeline of LAG-3 inhibitors in clinical pipeline. Apart from monoclonal antibodies, researchers have also developed bispecific antibodies which not only enhances efficacy but also reduces the overall cost of therapy. For instance, Tebotelimab developed by Macrogenics is an investigational, first-in-class bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. In addition, FS118 developed by F-star Therapeutics is also LAG-3/PD-L1 bispecific antibody in clinical trials.
In last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to help overcome some of the challenges the industry is facing. The industry is recognizing and has to recognize the expertise that is available and will have positive effects on everyone that works in pharmaceuticals. Recently in December, 2021 BeiGene and Najing Leads Biolab have announced worldwide license and collaboration agreement for development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, anti-LAG-3 antibody.
With the growing incidences of cancer due to the deteriorating environment, drastic climate changes, and rise in the number of smokers, the global LAG-3 inhibitors market is projected to grow unboundedly during the forecast period. The patients are increasingly becoming aware about novel targeted cancer therapy due to the constant efforts taken by government, which will further aid in the growth of market. The market is also driven by the continuous research and development made by research institutions and pharmaceutical companies.
As per report findings, the global LAG-3 inhibitor market is expected to surpass US$ 2 Billion by 2028. The report provides a detailed analysis of the global LAG-3 checkpoint inhibitors market and also provides the current and forecasted market for LAG-3 inhibitors. Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for the growth of the global LAG-3 inhibitors market during the forecast period. A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the LAG-3 inhibitors programs at various stages of clinical development.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366